Toshiba America Medical Systems, Inc. has introduced Volume Navigation 3D, a roadmapping solution intended for use with any model in its InfinixTM-i vascular X-ray product line.

The average per capita cost of healthcare services covered by commercial insurance and Medicare programs is on an upward trend, rising by 6.29% over the year ending in January, according to Standard & Poor’s S&P Healthcare Economic Composite Index. The increase marks the first time the growth rate has accelerated since May 2010.

Positron Corporation, a molecular imaging company specializing in the field of nuclear cardiology, yesterday announced plans to introduce an automated radiopharmaceutical system, at two upcoming industry conferences.

The U.S. breast imaging and mammography market will recover from the recession and double in value over the next decade, as clinics replace old film units and adopt new molecular imaging technologies, according to a new report. 

IData Research, a market research firm, estimates the breast imaging market will reach $1 billion by 2017. Hologic Inc.

World Class CME, a Fort Mill, S.C.-based physician-founded company that provides continuing medical education in the areas of radiology, ultrasound, gynecology, and sleep medicine, is now accepting registrations for a breast biopsy workshop designed to provide radiologists with the FDA-mandated eight hours of case-based training in three

A New Jersey representative has introduced to the U.S. House of Representatives legislation that would bar group health plans and health insurance issuers from denying coverage for preventive services, including mammograms as a result of federal guidelines.

Virtual Radiologic (vRad), a technology-enabled national radiology practice whose 325 radiologists serve 2,700-plus facilities and read seven million studies annually, earlier this week announced the launch of a breast imaging solutions delivery program it says will expand access to “the highest-quality interpretations” from fellowship-trained

Gadavist (gadobutrol), a gadolinium-based contrast agent (GBCA), has received FDA approval for use in patients undergoing MRI of the central nervous system. Manufactured by Bayer Pharmaceuticals, Gadavist provides contrast-enhanced imaging of the central nervous system, helping to detect and visualize lesions that disrupt the cell barrier that